Moment of Clarity has published a new educational resource on insurance coverage considerations for transcranial magnetic ...

Swedish neurotech startup Flow Neuroscience has secured FDA approval for the first brain stimulation device for home use in ...

BrainsWay’s SWIFT depression protocol consists of an acute phase of five treatment sessions (ten minutes each) per day for ...

Program will integrate existing neurocare clinics with HOPE Therapeutics clinics and will engage the already-installed base ...

Because of rising rates of anxiety, depression and other mental health concerns among adolescents, TMS has been used off-label for many years to treat depression among teenagers. The US Centers for ...

BrainsWay Ltd. BWAY recently announced an expansion of insurance coverage for its Deep TMS therapy in adolescent depression. The update signals growing payer confidence in non-drug neurostimulation ...

(RTTNews) - Neuronetics, Inc. (STIM), a neurohealth technology company, on Wednesday announced the publication of two significant peer-reviewed studies in the inaugural issue of the Transcranial ...

BURLINGTON, Mass. and JERUSALEM, Oct. 16, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (BWAY) (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation ...

NEW YORK ― Transcranial magnetic stimulation (TMS) is a cost-effective treatment option for patients with resistant major depressive disorder (MDD), according to a new economic analysis. "It's mainly ...

The Horizon® 3.0 Inspire has a compact design allowing for easier portability. The Food and Drug Administration (FDA) has cleared Magstim’s Horizon ® 3.0 Inspire for the treatment of major depressive ...

Radial reports that teen depression is prevalent yet under-treated. Effective options include therapy, antidepressants, and ...